Biogen 4Q Revenue Tops Wall Street's Estimates

Dow Jones

Feb 12, 2025

By Denny Jacob

Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line.

The biotechnology pioneer on Wednesday said it logged net income of $266.8 million, or $1.83 a share, compared to $249.7 million, or $1.71 a share, a year earlier.

Stripping out certain one-time items, earnings came in at $3.44 a share. Analysts polled by FactSet expected $3.35 a share in adjusted earnings.

Revenue rose to $2.45 billion from $2.39 billion. Analysts expected $2.41 billion.

Biogen said revenue from product launches continued to offset year-over-year declines in multiple-sclerosis product revenue.

The Cambridge, Mass., company forecast revenue in 2025 to decline by a mid-single-digit percentage at constant currency compared with 2024. Biogen also guided for full-year adjusted earnings per share of between $15.25 and $16.25; analysts expected $16.33 a share in adjusted earnings.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

February 12, 2025 07:23 ET (12:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510737763"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510737763\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510737763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510737763","market":"sg","top_or_hot":-1,"title":"Biogen 4Q Revenue Tops Wall Street's Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line. \n</p>\n<p>\n  The biotechnology pioneer on Wednesday said it logged net income of $266.8 million, or $1.83 a share, compared to $249.7 million, or $1.71 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, earnings came in at $3.44 a share. Analysts polled by FactSet expected $3.35 a share in adjusted earnings. \n</p>\n<p>\n  Revenue rose to $2.45 billion from $2.39 billion. Analysts expected $2.41 billion. \n</p>\n<p>\n  Biogen said revenue from product launches continued to offset year-over-year declines in multiple-sclerosis product revenue. \n</p>\n<p>\n  The Cambridge, Mass., company forecast revenue in 2025 to decline by a mid-single-digit percentage at constant currency compared with 2024. Biogen also guided for full-year adjusted earnings per share of between $15.25 and $16.25; analysts expected $16.33 a share in adjusted earnings. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2025 07:23 ET (12:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen 4Q Revenue Tops Wall Street's Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen 4Q Revenue Tops Wall Street's Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-12 20:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n  Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line. \n</p>\n<p>\n  The biotechnology pioneer on Wednesday said it logged net income of $266.8 million, or $1.83 a share, compared to $249.7 million, or $1.71 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-time items, earnings came in at $3.44 a share. Analysts polled by FactSet expected $3.35 a share in adjusted earnings. \n</p>\n<p>\n  Revenue rose to $2.45 billion from $2.39 billion. Analysts expected $2.41 billion. \n</p>\n<p>\n  Biogen said revenue from product launches continued to offset year-over-year declines in multiple-sclerosis product revenue. \n</p>\n<p>\n  The Cambridge, Mass., company forecast revenue in 2025 to decline by a mid-single-digit percentage at constant currency compared with 2024. Biogen also guided for full-year adjusted earnings per share of between $15.25 and $16.25; analysts expected $16.33 a share in adjusted earnings. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 12, 2025 07:23 ET (12:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2510737763","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510737763","pubTimestamp":1739362980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line.The biotechnology pioneer on Wednesday said it logged net income of $266.8 million, or $1.83 a share, compared to $249.7 million, or $1.71 a share, a year earlier.Stripping out certain one-time items, earnings came in at $3.44 a share. Analysts polled by FactSet expected $3.35 a share in adjusted earnings.Revenue rose to $2.45 billion from $2.39 billion. Analysts expected $2.41 billion.Biogen said revenue from product launches continued to offset year-over-year declines in multiple-sclerosis product revenue.The Cambridge, Mass., company forecast revenue in 2025 to decline by a mid-single-digit percentage at constant currency compared with 2024. Biogen also guided for full-year adjusted earnings per share of between $15.25 and $16.25; analysts expected $16.33 a share in adjusted earnings.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"百健(Biogen)第四季度收入超出华尔街预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"By Denny Jacob \n\n\n \n\n\n  Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line. \n\n\n  The biotechnology pioneer on Wednesday said it logged net income of $266.8 million, or $1.83 a share, compared to $249.7 million, or $1.71 a share, a year earlier. \n\n\n  Stripping out certain one-time items, earnings came in at $3.44 a share. Analysts polled by FactSet expected $3.35 a share in adjusted earnings. \n\n\n  Revenue rose to $2.45 billion from $2.39 billion. Analysts expected $2.41 billion. \n\n\n  Biogen said revenue from product launches continued to offset year-over-year declines in multiple-sclerosis product revenue. \n\n\n  The Cambridge, Mass., company forecast revenue in 2025 to decline by a mid-single-digit percentage at constant currency compared with 2024. Biogen also guided for full-year adjusted earnings per share of between $15.25 and $16.25; analysts expected $16.33 a share in adjusted earnings. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 12, 2025 07:23 ET (12:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}